David A. Spellman - Feb 28, 2022 Form 4 Insider Report for Akebia Therapeutics, Inc. (AKBA)

Signature
/s/ Carolyn Rucci, attorney-in-fact for David A. Spellman
Stock symbol
AKBA
Transactions as of
Feb 28, 2022
Transactions value $
-$17,689
Form type
4
Date filed
3/2/2022, 08:09 PM
Previous filing
Oct 1, 2021
Next filing
Jun 10, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKBA Common Stock Sale -$15.9K -7.4K -9.64% $2.15 69.4K Feb 28, 2022 Direct F1
transaction AKBA Common Stock Award $0 +60K +86.45% $0.00 129K Feb 28, 2022 Direct F2
transaction AKBA Common Stock Sale -$1.74K -803 -0.62% $2.17 129K Mar 1, 2022 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKBA Employee Stock Option (Right to buy) Award $0 +225K $0.00 225K Feb 28, 2022 Common Stock 225K $2.16 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021.
F2 The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date.
F3 This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021.
F4 The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.